BI 2536 Infusional Treatment in Patients Over 60 Years of Age With Refractory or Relapsed Acute Myeloid Leukaemia

NCT00701766 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

71

Enrollment

INDUSTRY

Sponsor class

Conditions

Leukemia, Myeloid, Acute

Interventions

DRUG: BI 2536

Sponsor

Boehringer Ingelheim